The flagship in the CerRx pipeline is the intravenous (emulsion) fenretinide (4-HPR) formulation (patents issued and licensed to CerRx). Phase II studies of intravenous emulsion fenretinide are being planned with the National Cancer Institute (NCI).
Building on the logical progression from 4-HPR single agent to a combination with a ceramide modulator (safingol), future CerRx endeavors will likely include the development of PPMP (a glucosylceramide synthase inhibitor that enhances activity of both 4-HPR and 4-HPR + safingol in preclinical studies).
Click on the chart below to view a larger version.
© CerRx, Inc. (2009-2018)